These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24815078)

  • 1. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
    Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
    Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL.
    Verbruggen B; Binder NB; van Velp PJC; Polenewen R; Knöbl P; Sobas F; Moore GW
    J Thromb Haemost; 2024 Oct; 22(10):2745-2751. PubMed ID: 38992344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
    Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
    Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophilia A and von Willebrand's disease.
    Goodeve AC; Rosén S; Verbruggen B
    Haemophilia; 2010 Jul; 16 Suppl 5():79-84. PubMed ID: 20590861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
    Berntorp E
    Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
    Feng HM; Li Q; Xu WS; Chen DM; Zheng L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
    Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
    Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
    Kim SY; Kang SY; Lee WI
    Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q; Schroeder JA; Kuether EL; Montgomery RR
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.